Cambridge-based Genzyme Corp. has started talks with Takeda Pharmaceutical Co. in a move to try to sell itself for more than $18.5 billion, the Mail on Sunday reported, citing a person familiar with the matter. (Full article: 121 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
